p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs

Journal of Experimental Medicine

Volumn 188, Issue 11, 1998, Pages 2033-2045

  Müller, Martina ^a,b   Wilder, Sylvia ^c   Bannasch, Detlev ^b   Israeli, David ^c   Lehlbach, Katrin ^a   Li Weber, Min ^b   Friedman, Scott L ^d   Galle, Peter R ^a   Stremmel, Wolfgang ^a   Oren, Moshe ^c   Krammer, Peter H ^b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^d MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Cancer therapy; CD95 (APO 1 Fas); Drug resistance; p53

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FAS ANTIGEN; FLUOROURACIL; METHOTREXATE; MITOMYCIN; MITOXANTRONE; MUTANT PROTEIN; PROTEIN P53; TAMOXIFEN;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER RESISTANCE; COLON CARCINOMA; CONTROLLED STUDY; DNA DAMAGE; DRUG MECHANISM; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; RECEPTOR UPREGULATION; STOMACH CARCINOMA; TRANSACTIVATION; TUMOR SUPPRESSOR GENE;

ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE SEQUENCE; DNA DAMAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031743648     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.188.11.2033     Document Type: Article

References (80)

1. Fisher, D.E. 1994. Apoptosis in cancer therapy: crossing the threshold. Cell. 78:539-542.
2. Fung, C.Y., and D.E. Fisher. 1995. Shifting the cancer paradigm: must we kill to cure? J. Clin. Oncol. 13:801-807.
3. Friesen, C., I. Herr, P.H. Krammer, and K.M. Debatin. 1996. Involvement of the CD95 (APO-1/Fas) receptor/ ligand system in drug-induced apoptosis in leukemia cells. Nat. Med. 2:574-580.
4. Micheau, O., E. Solary, A. Hammann, F. Martin, and B.M. Dimanche. 1997. Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity. J. Natl. Cancer Inst. 89:783-789.
5. Fulda, S., H. Sieverts, C. Friesen, I. Herr, and K.M. Debatin. 1997. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res. 57: 3823-3829.
6. Müller, M., S. Strand, H. Hug, E.-M. Heinemann, H. Walczak, W.J. Hofmann, W. Stremmel, P.H. Krammer, and P.R. Galle. 1997. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J. Clin. Invest. 99:403-413.
7. Tamura, T., N. Aoyama, H. Saya, H. Haga, S. Futami, M. Miyamoto, T. Koh, T. Ariyasu, M. Tachi, M. Kasuga, and R. Takahashi. 1995. Induction of Fas-mediated apoptosis in p53-transfected human colon carcinoma cells. Oncogene. 11: 1939-1946.
8. Miyake, H., I. Hara, K. Gohji, S. Arakawa, and S. Kamidono. 1998. p53 modulation of Fas/Apo-1 mediated apoptosis in a human renal cell carcinoma cell line. Int. J. Oncol. 12: 469-473.
9. Egle, A., A. Villunger, I. Marschitz, M. Kos, A. Hittmair, P. Lukas, K. Grunewald, and R. Greil. 1997. Expression of Apo-1/Fas (CD95), Bcl-2, Bax and Bcl-x in myeloma cell lines: relationship between responsiveness to anti-Fas mab and p53 functional status. Br. J. Haematol. 97:418-428.
10. Fuchs, E.J., K.A. McKenna, and A. Bedi. 1997. p53-dependent DNA damage-induced apoptosis requires Fas/APO-1-independent activation of CPP32β. Cancer Res. 57:2550-2554.
11. Harris, C.C. 1996. p53 tumor suppressor gene: from the basic research laboratory to the clinic - an abridged historical perspective. Carcinogenesis. 17:1187-1198.
12. Harris, C.C. 1996. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J. Natl. Cancer Inst. 88:1442-1455.
13. Levine, A.J. 1997. p53, the cellular gatekeeper for growth and division. Cell. 88:323-331.
14. Kastan, M.B., O. Onyekwere, D. Sidransky, B. Vogelstein, and R.W. Craig. 1991. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:6304-6311.
15. Kuerbitz, S.J., B.S. Plunkett, W.V. Walsh, and M.B. Kastan. 1992. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA. 89:7491-7495.
16. Clarke, A.R., C.A. Purdie, D.J. Harrison, R.G. Morris, C.C. Bird, M.L. Hooper, and A.H. Wyllie. 1993. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature. 362:849-852.
17. Lotem, J., and L. Sachs. 1993. Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. Blood. 82:1092-1096.
18. Lowe, S.W., H.E. Ruley, T. Jacks, and D.E. Housman. 1993. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74:957-967.
19. Lowe, S.W., E.M. Schmitt, S.W. Smith, B.A. Osborne, and T. Jacks. 1993. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature. 362:847-849.
20. Smith, M.L., I.T. Chen, Q. Zhan, I. Bae, C.Y. Chen, T.M. Gilmer, M.B. Kastan, P.M. O'Connor, and A.J. Fornace, Jr. 1994. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science. 266:1376-1380.
21. Smith, M.L., I.T. Chen, Q. Zhan, P.M. O'Connor, and A.J. Fornace, Jr. 1995. Involvement of the p53 tumor suppressor in repair of u.v.-type DNA damage. Oncogene. 10:1053-1059.
22. Wang, X.W., H. Yeh, L. Schaeffer, R. Roy, V. Moncollin, J.M. Egly, Z. Wang, E.C. Freidberg, M.K. Evans, B.G. Taffe, et al. 1995. p53 modulation of TFIIH-associated nucleotide excision repair activity. Nat. Genet. 10:188-195.
23. El-Deiry, W.S., T. Tokino, V.E. Velculescu, D.E. Levy, R. Parsons, J.M. Trent, D. Lin, W.E. Mercer, K.W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell. 75:817-825.
24. Waldman, T., K.W. Kinzler, and B. Vogelstein. 1995. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 55:5187-5190.
25. Deng, C., P. Zhang, J.W. Harper, S.J. Elledge, and P. Leder. 1995. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell. 82: 675-684.
26. Brugarolas, J., C. Chandrasekaran, J.I. Gordon, D. Beach, T. Jacks, and G.J. Hannon. 1995. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature. 377:552-557.
27. Miyashita, T., S. Krajewski, M. Krajewska, H.G. Wang, H.K. Lin, D.A. Liebermann, B. Hoffman, and J.C. Reed. 1994. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 9:1799-1805.
28. Yin, C., C.M. Knudson, S.J. Korsmeyer, and D.T. Van. 1997. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature. 385:637-640.
29. Owen-Schaub, L.B., W. Zhang, J.C. Cusack, L.S. Angelo, S.M. Santee, T. Fujiwara, J.A. Roth, A.B. Deisseroth, W.W. Zhang, E. Kruzel, and R. Radinsky. 1995. Wild-type human p53 and a temperature-sensitive mutant induce FAS/APO-1 expression. Mol. Cell. Biol. 15:3032-3040.
30. Aden, D.P., A. Fogel, S. Plotkin, I. Damjanov, and B.B. Knowles. 1979. Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature. 282: 615-616.
31. Ponchel, F., A. Puisieux, E. Tabone, J.P. Michot, G. Froschl, A.P. Morel, T. Frebourg, B. Fontaniere, F. Oberhammer, and M. Ozturk. 1994. Hepatocarcinoma-specific mutant p53-249ser induces mitotic activity but has no effect on transforming growth factor beta 1-mediated apoptosis. Cancer Res. 54:2064-2068.
32. Nakabayashi, H., K. Taketa, T. Yamane, M. Miyazaki, K. Miyano, and J. Sato. 1984. Phenotypical stability of a human hepatoma cell line, HuH-7, in long-term culture with chemically defined medium. Jpn. J. Cancer Res. 75:151-158.
33. Hsu, I.C., T. Tokiwa, W. Bennett, R.A. Metcalf, J.A. Welsh, T. Sun, and C.C. Harris. 1993. p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. Carcinogenesis. 14:987-992.
34. Huang, F., S. Hsu, Z. Yan, S. Winawer, and E. Friedman. 1994. The capacity for growth stimulation by TGF beta 1 seen only in advanced colon cancers cannot be ascribed to mutations in APC, DCC, p53 or ras. Oncogene. 9:3701-3706.
35. Little, J.B., H. Nagasawa, P.C. Keng, Y. Yu, and C.Y. Li. 1995. Absence of radiation-induced G1 arrest in two closely related human lymphoblast cell lines that differ in p53 status. J. Biol. Chem. 270:11033-11036.
36. Plummer, S.J., L. Adams, J.A. Simmons, and G. Casey. 1997. Localization of a growth suppressor activity in MCF7 breast cancer cells to chromosome 17q24-q25. Oncogene. 14:2339-2345.
37. Blagosklonny, M.V., T.W. Schulte, P. Nguyen, E.G. Mimnaugh, J. Trepel, and L. Neckers. 1995. Taxol induction of p21WAF1 and p53 requires c-raf-1. Cancer Res. 55:4623-4626.
38. Mitsudomi, T., S.M. Steinberg, M.M. Nau, D. Carbone, D. D'Amico, S. Bodner, H.K. Oie, R.I. Linnoila, J.L. Mulshine, and J.D. Minna. 1992. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene. 7:171-180.
39. Haupt, Y., S. Rowan, and M. Oren. 1995. p53-mediated apoptosis in HeLa cells can be overcome by excess pRB. Oncogene. 10:1563-1571.
40. Eliyahu, D., D. Michalovitz, S. Eliyahu, O. Pinhasi-Kimhi, and M. Oren. 1989. Wild-type p53 can inhibit oncogene-mediated focus formation. Proc. Natl. Acad. Sci. USA. 86: 8763-8767.
41. Friedman, S.L., E. Shaulian, T. Littlewood, D. Resnitzky, and M. Oren. 1997. Resistance to p53-mediated growth arrest and apoptosis in Hep 3B hepatoma cells. Oncogene. 15: 63-70.
42. Michalovitz, D., O. Halevy, and M. Oren. 1990. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell. 62:671-680.
43. -/- mouse embryo fibroblasts. Oncogene. 13:739-748.
44. Zhang, W., X.Y. Guo, G.Y. Hu, W.B. Liu, J.W. Shay, and A.B. Deisseroth. 1994. A temperature-sensitive mutant of human p53. EMBO (Eur. Mol. Biol. Organ.) J. 13:2535-2544.
45. Hall, S.W., J.E. Strong, A. Broughton, M.L. Frazier, and R.S. Benjamin. 1982. Bleomycin clinical pharmacology by radioimmunoassay. Cancer Chemother. Pharmacol. 9:22-25.
46. Shea, T.C., M. Flaherty, A. Elias, J.P. Eder, K. Antman, C. Begg, L. Schnipper, E. Frei III, and W.D. Henner. 1989. A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. J. Clin. Oncol. 7:651-661.
47. Kurihara, N., T. Kubota, Y. Hoshiya, Y. Otani, N. Ando, K. Kumai, and M. Kitajima. 1996. Pharmacokinetics of cis-diamminedichloroplatinum (II) given as low-dose and high-dose infusions. J. Surg. Oncol. 62:135-138.
48. Evans, W.E., W.R. Crom, M. Abromowitch, R. Dodge, A.T. Look, W.P. Bowman, S.L. George, and C.-H. Pui. 1986. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. N. Engl. J. Med. 314:471-477.
49. Muller, C., E. Chatelut, V. Gualano, M. De Forni, F. Huguet, M. Attal, P. Canal, and G. Laurent. 1993. Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion. Cancer Chemother. Pharmacol. 32: 379-384.
50. Trauth, B.C., C. Klas, A.J.M. Peters, S. Matzku, P. Möller, W. Falk, K.M. Debatin, and P.H. Krammer. 1989. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science. 245:301-305.
51. Dhein, J., P.T. Daniel, B.C. Trauth, A. Oehm, P. Möller, and P.H. Krammer. 1992. Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens. J. Immunol. 149:3166-3173.
52. Dhein, J., H. Walczak, C. Bäumler, K.M. Debatin, and P.H. Krammer. 1995. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature. 373:438-441.
53. Nicoletti, I., G. Migliorati, M.C. Paggliacci, F. Grignani, and C. Riccardi. 1991. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods. 139:271-279.
54. Peter, M.E., J. Dhein, A. Ehret, S. Hellbardt, H. Walczak, G. Moldenhauer, and P.H. Krammer. 1995. APO-1(CD95)-dependent and -independent antigen receptor-induced apoptosis in human T and B cell lines. Int. Immunol. 7:1873-1877.
55. Behrmann, I., H. Walczak, and P.H. Krammer. 1994. Structure of the human APO-1 gene. Eur. J. Immunol. 24:3057-3062.
56. Zauberman, A., Y. Barak, N. Ragimov, N. Levy, and M. Oren. 1993. Sequence-specific DNA binding by p53: identification of target sites and lack of binding to p53-MDM2 complexes. EMBO (Eur. Mol. Biol. Organ.) J. 12:2799-2808.
57. Wada, N., M. Matsumura, Y. Ohba, N. Kobayashi, T. Takizawa, and Y. Nakanishi. 1995. Transcription stimulation of the Fas-encoding gene by nuclear factor for interleukin-6 expression upon influenza virus infection. J. Biol. Chem. 270: 18007-18012.
58. Rudert, F., E. Visser, L. Forbes, E. Lindridge, Y. Wang, and J. Watson. 1995. Identification of a silencer, enhancer, and basal promoter region in the human CD95 (Fas/APO-1) gene. DNA Cell Biol. 14:931-937.
59. Zauberman, A., A. Lupo, and M. Oren. 1995. Identification of p53 target genes through immune selection of genomic DNA: the cyclin G gene contains two distinct p53 binding sites. Oncogene. 10:2361-2366.
60. Steel, G.G., and M.J. Peckham. 1979. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int. J. Radiat. Oncol. Biol. Phys. 5:85-91.
61. Chou, T.C., and P. Talalay. 1984. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22:27-55.
62. Fritsche, M., C. Haessler, and G. Brandner. 1993. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents [erratum in 8:2605]. Oncogene. 8:307-318.
63. El-Deiry, W.S., S.E. Kern, J.A. Pietenpol, K.W. Kinzler, and B. Vogelstein. 1992. Definition of a consensus binding site for p53. Nat. Genet. 1:45-49.
64. Strand, S., W.J. Hofmann, H. Hug, M. Müller, G. Otto, D. Strand, S.M. Mariani, W. Stremmel, P.H. Krammer, and P.R. Galle. 1996. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nat. Med. 2:1361-1366.
65. French, L.E., M. Hahne, I. Viard, G. Radlgruber, R. Zanone, K. Becker, C. Muller, and J. Tschopp. 1996. Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J. Cell Biol. 133:335-343.
66. Niehans, G.A., T. Brunner, S.P. Frizelle, J.C. Liston, C.T. Salerno, D.J. Knapp, D.R. Green, and R.A. Kratzke. 1997. Human lung carcinomas express Fas ligand. Cancer Res. 57: 1007-1012.
67. O'Connell, J., G.C. O'Sullivan, J.K. Collins, and F. Shanahan. 1996. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 184: 1075-1082.
68. Stuart, P.M., T.S. Griffith, N. Usui, J. Pepose, X. Yu, and T.A. Ferguson. 1997. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J. Clin. Invest. 99: 396-402.
69. Griffith, T.S., T. Brunner, S.M. Fletcher, D.R. Green, and T.A. Ferguson. 1995. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 270:1189-1192.
70. Bellgrau, D., D. Gold, H. Selawry, J. Moore, A. Franzusoff, and R.C. Duke. 1995. A role for CD95 ligand in preventing graft rejection. Nature. 377:630-632.
71. Griffith, T.S., X. Yu, J.M. Herndon, D.R. Green, and T.A. Ferguson. 1996. CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. Immunity. 5:7-16.
72. Seino, K., N. Kayagaki, K. Okumura, and H. Yagita. 1997. Antitumor effect of locally produced CD95 ligand. Nat. Med. 3:165-170.
73. Kastan, M.B., Q. Zhan, W.S. El-Deiry, F. Carrier, T. Jacks, W.V. Walsh, B.S. Plunkett, and B. Vogelstein. 1992. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell. 71:587-597.
74. Zauberman, A., D. Flusberg, Y. Haupt, Y. Barak, and M. Oren. 1995. A functional p53-responsive intronic promoter is contained within the human mdm2 gene. Nucleic Acids Res. 23:2584-2592.
75. Okamoto, K., and D. Beach. 1994. Cyclin G is a transcriptional target of the p53 tumor suppressor protein. EMBO (Eur. Mol. Biol. Organ.) J. 13:4816-4822.
76. Werner, H., E. Karnieli, F.J. Rauscher III, and D. Leroith. 1996. Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc. Natl. Acad. Sci. USA. 93:8318-8323.
77. Roth, J.A., D. Nguyen, D.D. Lawrence, B.L. Kemp, C.H. Carrasco, D.Z. Ferson, W.K. Hong, R. Komaki, J.J. Lee, J.C. Nesbitt, et al. 1996. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat. Med. 2:985-991.
78. Fujiwara, T., E.A. Grimm, T. Mukhopadhyay, W.W. Zhang, S.L. Owen, and J.A. Roth. 1994. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res. 54:2287-2291.
79. Nguyen, D.M., F.R. Spitz, N. Yen, R.J. Cristiano, and J.A. Roth. 1996. Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer. J. Thorac. Cardiovasc. Surg. 112:1372-1376.
80. Wu, G.S., T.F. Burns, E.R. McDonald, W. Jiang, R. Meng, I.D. Krantz, G. Kao, D.D. Gan, J.Y. Zhou, R. Muschel, et al. 1997. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat. Genet. 17:141-143.